Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NO-CUT trial in locally advanced rectal cancer
2017-003671-60Phase 2Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal adenocarcinoma and colorectal adenocarcinoma, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Distant relapse-free survival rate at 2.5 years. Started Dec 2020; status: active.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on 2017-003671-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003671-60.